EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejection
pharmaphorum
JUNE 11, 2021
Sanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) were dashed by the FDA, but new phase 3 data keep the drugmaker on track for a resubmission before year-end. Sutimlimab, which Sanofi acquired via its $11.6
Let's personalize your content